Key Takeaways
- Clinical Bottom Line
- Endoscopic Evaluation of Peptic Ulcer Disease (PUD)
Clinical Bottom Line
| Clinical Variable | Guideline Recommendation | Therapeutic Intent |
|---|---|---|
| Gastric Ulcers | Mandatory routine biopsies of the ulcer edge. | Ruling out underlying gastric adenocarcinoma presenting as a benign ulcer. |
| Duodenal Ulcers | Biopsies of the ulcer are NOT routinely recommended. | Malignancy in the duodenal bulb is exceptionally rare; risk of bleeding outweighs benefits. |
| Helicobacter pylori | Antral and Corpal biopsies required for ALL presenting PUD. | Identifying the primary bacterial driver to direct eradication therapy. |
Endoscopic Evaluation of Peptic Ulcer Disease (PUD)
While the incidence of severe Peptic Ulcer Disease has declined with the widespread use of prophylactic proton pump inhibitors (PPIs) and the gradual eradication of H. pylori, it remains a primary indication for urgent outpatient upper endoscopy. According to the 2026 ASGE guidelines, the location of the ulcer fundamentally alters the endoscopist’s mucosal sampling strategy.
The Malignancy Rule
A gastric ulcer is considered malignant until proven otherwise. Endoscopists must vigorously biopsy all four quadrants of the ulcer margin (not the necrotic base, which returns only useless slough). Furthermore, any gastric ulcer initially evaluated requires a mandatory repeat EGD 8 to 12 weeks later to visually confirm complete healing; failure to heal strongly suggests an occult gastric cancer. Conversely, duodenal ulcers are almost universally benign and do not require interval surveillance EGDs if symptoms resolve.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.
